#United States #Pleasanton #Health Technology #Movano Health #Nasdaq MOVE

Movano Health's Path Forward Following Nasdaq Delisting Notice

On July 7, 2025, Movano Health (Nasdaq: MOVE) received a distressing notification from The Nasdaq Capital Market, indicating that the company no longer meets certain requirements necessary for its stock to remain listed. The notice was primarily concerning two key areas: the bid price of its shares and the timely filing of its financial reports. With a bid price that had fallen below the essential threshold of $1.00 per share for a consecutive 30-day trading period, Movano Health found itself facing the potential of delisting.

Delisting Determination and Requirements

The delisting determination cited two main violations. Firstly, Movano had not complied with the Bid Price Requirement, as outlined in Listing Rule 5550(a)(2). Secondly, a Filing Requirement related to their Form 10-Q submission for the quarter ended March 31, 2025, was also identified as late according to Listing Rule 5250(c)(1). Given these circumstances, the company plans to formally request a hearing before a Nasdaq Hearings Panel, a critical step in attempting to contest the delisting decision.

In light of the notification, Movano Health has taken immediate action by planning to file for a hearing, which they hope will grant them what is known as an extended stay. This would temporarily pause the pending suspension and delisting process while the hearing is underway. However, it should be noted that without the Panel's approval of the extended stay, Movano will only enjoy a limited grace period of 22 calendar days following the notice.

Challenges Ahead for Movano Health

This situation arises against a backdrop of recent operational challenges faced by the company, including a significant reverse stock split undertaken in the previous year. Such measures typically distort compliance periods, making it difficult for companies to regain their footing when faced with downtrodden stock prices. Movano Health’s circumstances highlight the precarious nature of being listed on Nasdaq, as the compliance landscape is rigorously enforced, especially after a disallowance of an eligible compliance period.

While the roadmap for appeal and hearings can offer a transient lifeline, it is important to note that there is no guarantee of a favorable outcome. The possibility remains that the Panel may deny Movano's requests and deny the company continued listing on Nasdaq altogether, which poses a tumultuous future path. Any potential decision against Movano will undoubtedly have reverberating effects on its operational capabilities and the overall confidence of investors.

About Movano Health

Movano Health has positioned itself as a pioneer in health technology since its inception in 2018. The company specializes in creating innovative health solutions and wearable devices designed to collect medical-grade data for consumers. They have unique capabilities that cater to individualized health monitoring and insights, which could be crucial in a time where personal health data is becoming increasingly vital for healthcare solutions.

Forward-Looking Statements

Despite the current setbacks, Movano Health remains committed to resolving compliance issues and continuing its forward trajectory in health technology. Investors and stakeholders should keep a close eye on how the upcoming hearings unfold and how the company maneuvers through these challenging waters. In an industry that relies heavily on data and technology, the next steps Movano Health takes will be crucial for both their reputation and ongoing viability in the market.

For ongoing updates, the company continues to engage with stakeholders through formal communications, directing those interested to visit Movano Health’s website.

As they navigate through this turbulent period, maintaining investor confidence will be paramount. The coming weeks will be telling for Movano Health's fate on Nasdaq and its future in the healthcare technology sector.